Article
Sanofi's latest analysis of Rezurock can inform future research, company says
Rating:
0.0
Views:
67
Likes:
1
Library:
1
After Kadmon scored its first FDA approval last summer, it took Sanofi | Sanofi has released pooled data from two trials of Rezurock that show a strong correlation between certain organ responses and improvements in patient-reported outcomes. The clinically meaningful changes in PROs were reported in the skin, mouth, eye, lung, upper gastrointestinal and overall measures.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value